Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RaSOLVE
NCT07269691Phase 3Not yet recruiting
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer (2 arms). Primary endpoint: Pathologic Complete Response. Planned start Dec 2025; status: not yet recruiting.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07269691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07269691.